Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

Inclusion: * Recurrent and/or metastatic resectable colorectal cancer, including disease within the abdomen and pelvis with no evidence of extra-abdominal metastases. Isolated resectable pulmonary metastasis are allowable in the absence of intra-abdominal metastasis. Intra-abdominal disease includes: isolated hepatic metastasis/metastases (see next inclusion criteria point), isolated peritoneal metastasis, peritoneal carcinomatosis (including patients undergoing cytoreductive surgery alone or in combination with hyperthermic intraperitoneal chemoperfusion - HIPEC), or a combination of hepatic and extrahepatic metastasis. * Patients with isolated hepatic metastasis must satisfy a Clinical Risk Score of 3 or higher (see Appendix C) * Eligible patients are expected to have a complete resection based on preoperative imaging. Any patient not found to be able to have complete resection will not be eligible for this study. * No chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of protocol treatment * An ECOG performance status of 0, 1, or 2. * Age equal to 18 years or older. * Must have normal organ and marrow function as defined below: * Platelet ≥ 75,000/µL * Hemoglobin ≥ 9.0 g/dL * Hematocrit ≥ 27.0% * Absolute Neutrophil Count (ANC) ≥ 1500/µL * Creatinine \< institutional upper limit of normal (ULN) OR * Creatinine clearance ≥ 50 mL/min/1.73 m2 for patients with creatinine levels greater than ULN * Total bilirubin ≤ 1.5 X institutional…